


Serial No. 10/623,972

Filed: July 21, 2003

**IN THE CLAIMS**

1. (Currently amended) A compound of formula:



I,

wherein

R<sup>1</sup> is selected from the group

- H,
- COR<sup>4</sup>, and
- COOCHR<sup>5</sup>OCOR<sup>4</sup>;

R<sup>2</sup> and R<sup>3</sup> are independently selected from

- H, and
- OR<sup>5</sup>;

R<sup>4</sup> is selected from the group

- C<sub>1-6</sub> alkyl,
- lower alkyl substituted by up to 4 groups independently selected from
- NR<sup>5</sup>R<sup>6</sup>,
- SR<sup>5</sup>,
- OR<sup>5</sup>,

Serial No. 10/623,972

Filed: July 21, 2003

-aryl,  
-aryl substituted by up to 2 groups independently selected from  
-OR<sup>5</sup> and C<sub>1-4</sub> lower alkyl, and  
-heteroaryl, and  
-heterocycle;

R<sup>5</sup> and R<sup>6</sup> are independently selected from  
-H, and  
- C<sub>1-6</sub> lower alkyl,

or, alternatively, -NR<sup>5</sup>R<sup>6</sup> can form a ring having 3 to 7 atoms, said ring optionally including one or more additional N or O atoms;

or the pharmaceutically acceptable salts thereof.

2. (Original) The compound of claim 1 wherein R<sup>1</sup> is -COR<sup>4</sup>.

3. (Original) The compound of claim 2 wherein R<sup>2</sup> is H.

4. (Original) The compound of claim 3 wherein R<sup>3</sup> is H.

5. (Previously presented) The compound of claim 4 which is selected from the group:

*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide;

*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide;

Serial No. 10/623,972

Filed: July 21, 2003

2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide acetic acid salt;

2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide hydrochloric acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide;

(2*S*)-2-amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide acetic acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide hydrochloric acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-3-phenyl-*N*-phenylpropanamide;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-3-phenyl-*N*-phenylpropanamide hydrochloric acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methyl-*N*-phenylpentanamide acetic acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methyl-*N*-phenylpentanamide hydrochloric acid salt;

(2*S*)-2-Amino-3-(4-hydroxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide hydrochloric acid salt;

Serial No. 10/623,972

Filed: July 21, 2003

(2*S*)-2,6-Diamino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]-*N*-phenylhexanamide di-hydrochloric acid salt;

(2*S*)-2-Amino-3-indol-3-yl-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]-*N*-phenylpropanamide hydrochloric acid salt ;

(2*S*)-2-Amino-3-hydroxy-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]-*N*-phenylpropanamide;

(2*R*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide hydrochloric acid salt;

*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]-*N*-phenylpentanamide; and

*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]-*N*-phenylbutanamide.

6. (Previously presented) The compound of claim 2 which is selected from the group:

*N*-(4-Hydroxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]acetamide; and

*N*-(4-methoxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-*d*]pyrimidin-7-yl)]acetamide.

7. (Original) The compound of claim 1 wherein R<sup>1</sup> is -COOCHR<sup>5</sup>OCOR<sup>4</sup>.

8. (Original) The compound of claim 7 wherein R<sup>2</sup> is H.

Serial No. 10/623,972

Filed: July 21, 2003

9. (Original) The compound of claim 8 wherein  $R^3$  is H.

10. (Previously presented) The compound of claim 9 which is selected from the group:

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl acetate;

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl 2-(dimethylamino)acetate;

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl 2-(dimethylamino)acetate hydrochloric acid salt; and

{*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl piperidine-4-carboxylate trifluoroacetic acid salt.

11. (Original) The compound of claim 1 wherein  $R^1$  is H.

12. (Original) The compound of claim 11 wherein  $R^2$  is H.

13. (Previously presented) The compound of claim 12 which is selected from the group:

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one;

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one methanesulfonate salt;

Serial No. 10/623,972

Filed: July 21, 2003

7-[(4-Hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one; and

3-(4-Methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one.

14. (Original) A compound selected from the group:

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one,

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one methanesulfonate salt,

7-[(4-Hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one, and

3-(4-Methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one.

15. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

Claim 16. (Canceled).

Claim 17. (Canceled).

Serial No. 10/623,972

Filed: July 21, 2003

18. (Previously presented) A method of- treating lung, colon or prostate cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1.

Claim 19. (Cancelled).

20. (Previously presented) A compound selected from the group:

(Chloromethoxy)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-benzamide,

3-(4-Methoxyphenyl)-1-phenyl-7-[[4-(1,1,2,2-tetramethyl-1-silapropoxy) phenyl]amino]-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one, and

*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-[4-(1,1,2,2-tetramethyl-1-silapropoxy)phenyl]acetamide.


Serial No. 10/623,972  
Filed: July 21, 2003

**REMARKS**

With entry of the present amendment claims 1-15, 18 and 20 are pending and are allowed. Claim 1 is amended to include a reference to pharmaceutically acceptable salts. This amendment is supported by the specification, for example at [0010]. Claim 19 is cancelled.

Applicants believe that no fee is due with this communication. However, should the Patent Office determine that a fee is owed, or a credit is due to applicant, the Patent Office is hereby authorized to charge any required fees, including any extension of time and/or excess claim fees, or credit any overpayment, to applicant's Deposit Account 08-2525 as appropriate.

Respectfully submitted,



Attorney for Applicant(s)  
Patricia S. Rocha-Tramaloní  
(Reg. No. 31,054)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-2441  
Telefax: (973) 235-2363

158096